RareScan
Rare Diseases
ResearchActive
Key Facts
About Constantiam Bio
Constantiam Biosciences is a private, pre-revenue biotech founded in 2020 and based in Cambridge, USA. It has developed a core technology platform integrating massively multiplexed functional assays with human genetic data and Bayesian machine learning to generate functional evidence for genetic variants. The company's primary focus is on serving the rare disease and oncology markets by providing tools and insights for VUS resolution, target discovery, and clinical trial optimization through its RareScan, Genable, StratiVar, and MAVEvidence platforms.
View full company profileTherapeutic Areas
Other Rare Diseases Drugs
| Drug | Company | Phase |
|---|---|---|
| Drug Development Program | MindMaze Therapeutics | Research |
| Undisclosed Rare Disease Program(s) | Base4 | Preclinical |
| Prognos Rare Disease | Prognos | Commercial |
| PEPRX101 | Peptris Technologies Private | In-vitro |